Yale Catriona

Akero Therapeutics, Inc. · Chief Development Officer

Yale Catriona is listed in filings as Chief Development Officer at Akero Therapeutics, Inc.. This profile follows SEC Form 4 activity through Dec 9, 2025, including sale activity. Recent filings connect the profile to Akero Therapeutics, Inc. (AKRO). The current snapshot covers public activity from Feb 21, 2025 to Dec 9, 2025. Reported amounts are shown as $3.6M to $2.1M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.

Data sources and methodology

Latest Trades

CompanyValueActionPriceLast Price
Akero Therapeutics, Inc.AKRO$28k659 sharesSellSep 11, 2025$43.02$54.65